Protocol Ledger

NCT03689244 · Phase III · TERMINATED

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Interventional Phase III clinical trial protocol NCT03689244 sponsored by Johnson & Johnson / Janssen in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-23 Enrollment: 128 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03689244
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)128 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03689244
Protocol FieldVerified Registry Value
NCT IdentifierNCT03689244
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment128 participants (ACTUAL)
Registered Start Date2019-01-23
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI